The approval of belzutifan, an oral hypoxia-inducible factor-2 alpha inhibitor, provides a new option for patients with advanced renal cell carcinoma (RCC) following treatment with a programmed death ...
Immune checkpoint inhibitors have significantly transformed the treatment paradigm for metastatic renal cell carcinoma (RCC), offering prolonged overall survival and achieving remarkable deep and ...
In the second part of a 2-part series, Rana R. McKay, MD, associate professor of Medicine and Urology, Moores Cancer Center, University of California San Diego, discusses second-line treatment options ...
A Japanese single-institution study suggests that axitinib may be a feasible first-line option for patients with locally advanced or metastatic renal cell carcinoma (RCC). Axitinib treatment resulted ...
The evaluation committee considered evidence submitted by Merck Serono, a review of this submission by the external assessment group (EAG) and responses from stakeholders. See the committee papers for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results